Grifols Breaks Ground on New IVIG Facility

    The new facility, based in Los Angeles, California is anticipated to be
    operational in 2013 and will expand the Company's ability to supply its
    generation of intravenous immune globulin into the foreseeable future.

    LOS ANGELES, Oct. 6 /CNW/ -- Today, Grifols SA (Grifols), a global
healthcare company based in Barcelona, Spain, broke ground on a new 92,000
square foot, intravenous immune globulin (IVIG) production facility at its
manufacturing complex in Los Angeles, California.  This new facility is the
initial realization of the $600 million long-range investment plan announced
in October 2007 to increase production for Grifols lifesaving coagulation
therapies, immune globulins and albumin.  Based on construction schedules and
rigorous regulatory licensing requirements, it is expected that the facility
will become operational for production of the Company's new generation IVIG
product in early 2013.
    The new facility represents an expansion of Grifols' existing
manufacturing capabilities in Los Angeles.  "We are committed to continuing to
grow our state of the art facilities in Los Angeles and giving back to the
community through the creation of new employment opportunities and economic
growth," said Gregory Rich, President of Grifols, Inc. the US subsidiary of
Grifols, SA.  The new facility will provide approximately 300 new jobs to the
Los Angeles community and represents an investment of greater than $50
    "We commend Grifols' increased commitment to the production of immune
globulin therapy.  Assuring continued access to this lifesaving medicine means
countless people who live with primary immunodeficienies, such as my son, can
lead healthy and productive lives," said Marcia Boyle, President and Founder
of the Immune Deficiency Foundation, the national patient organization for
persons with primary immune diseases.  Demand for IVIG has seen steady growth
over the past ten years in the US, Europe and other international markets.
    Grifols' new production facility will almost double the company's IVIG
production capacity and will utilize the same proprietary technologies and
process flow designs employed at the company's existing IVIG production
facility in Barcelona, Spain that have been pioneered by Grifols Engineering
S.A., a wholly owned subsidiary of Grifols S.A.  In effect, the new facility
will be a twin of the Company's IVIG facility in Barcelona, Spain that was
licensed by the US Food and Drug Administration (FDA) last year.
    Building this additional production capacity represents one more step in
Grifols' multi-year global growth plan to meet increasing patient need for
lifesaving plasma therapies.  Other elements of the long-range investment plan
include expanding plasma collection capacity and additional production and
testing facilities.  Earlier this year the Company obtained FDA approval of
its state of the art bulk processing and aseptic filling facility at its Los
Angeles manufacturing complex.
    About Grifols
    Grifols SA (Grifols) is a global healthcare company founded in 1940 in
Barcelona, Spain.  Today Grifols products and services are provided in more
than 90 countries around the world.  Grifols specializes in the production of
plasma therapies to treat a variety of life-threatening diseases and
conditions.  Grifols operates 80 plasma donor centers throughout the US and
has manufacturing facilities located in Barcelona, Spain and Los Angeles,
California.  For more information about Grifols please visit

For further information:

For further information: Chris Healey of Grifols, Inc., +1-703-351-5004,
or fax, +1-703-276-9052, Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890